Amyris, the industrial bioscience company, and Koninklijke DSM N.V. (Royal DSM), the global science-basedcompany active in health, nutrition and materials, announced that they have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).Amyris’ technology supports DSM’s strategic markets in health, nutrition, and materials as well as a growing consumer shift to bio-based products derived from sustainable sources. For Amyris, DSM’s channels, market access and keen understanding in selecting the right products for the animal nutrition, human nutrition, and consumer health markets provide strategic value.
“Amyris has a unique yeast-based strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how.”
Royal DSM ( @DSM)delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.
Amyris (@Amyris)applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals.
“Amyris has a unique yeast-based strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how in fermentation, downstream process development and large-scale manufacturing,” said Chris Goppelsroeder, President & CEO of DSM Nutritional Products.
“Working closely together with Amyris and leveraging DSM’s route-to-market, will accelerate our innovation towards cost-effective, fermentation-based processes for both existing and new products.”
DSM has agreed to make an initial equity investment in Amyris of US$25 million, translating into a shareholding of ~12%. Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris. The first tranche is expected to close on Thursday, 11 May 2017, with a second tranche, if approved by DSM’s Managing Board, expected to close within 90 days of the closing of the first tranche. As part of this investment, DSM will gain one board seat upon the closing of each tranche.
As part of the agreement, DSM and Amyris have agreed to focus on a number of short- to medium-term product development & production opportunities in vitamins and other nutritional ingredients.
“We are very excited about DSM’s strategic focus in health and nutrition markets and its commitment to sustainable sourcing and production of better-performing products,” said John Melo, Amyris President & CEO.
“The Amyris technology platform and potential synergy can lead to significant cost improvements for DSM while accelerating Amyris’s market access. We expect this will lead to incremental revenue in 2017, growing annually based on the number of products we develop in our partnership and our pace of delivery.”
Terms of the private placement and related agreements are more fully disclosed in the Form 8-K filed by Amyris today with the Securities and Exchange Commission, available free of charge at sec.gov.
To read about more collaborations in the bio-based space you might be interested in: